QIAGEN Announces FDA Approval of PartoSureTM

Novel point-of-care test to assess risk of spontaneous preterm birth, reducing unnecessary hospital admissions and safeguarding babies

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of PartoSureTM , which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor. The pre-market approval of PartoSure by the U.S. Food and Drug Administration (FDA) follows successful uptake of the rapid, accurate test in more than 35 countries across Europe, the Middle East, Asia and Latin America. U.S. commercialization of the PartoSure test is expected to begin in 2018.

PartoSure represents a key milestone in the development of diagnostic tests for preterm birth. A non-invasive strip test that provides results in five minutes or less, PartoSure has been shown in several published studies to have a higher positive predictive value for preterm birth compared to current diagnostic methods, while maintaining an equally high negative predictive value. The novel test detects placental alpha microglobulin-1 (PAMG-1) in patients presenting with signs and symptoms of preterm labor.

PartoSure adds to QIAGEN’s comprehensive Sexual and Reproductive Health portfolio, which includes the AmniSure® ROM Test, the world’s leading assay for rupture of membranes (ROM); differentiated core technologies and bioinformatics solutions for non-invasive prenatal testing (NIPT); and the “gold standard” digene HC2 HPV Test to screen for human papillomavirus (HPV) and protect women from cervical cancer. The combination of PartoSure and AmniSure gives QIAGEN two highly synergistic, biomarker targeted diagnostics for assessing the risk of two critical aspects of prenatal labor management. Both tests are leveraging the ability to assess respective risks quickly without the requirement of a reader.

Please find the full press release here

###

View source version on businesswire.com: https://www.businesswire.com/news/home/20180419006112/en/

QIAGENInvestor RelationsJohn Gilardi+49 2103 29 11711e-mail: [e-mail] RelationsDr. Thomas Theuringer+49 2103 29 11826e-mail: [e-mail]